No evidence of toxicity was observed in 4T1 tumor-bearing mice treated six times with Nucl-TAP in terms of changes in organ weight (Fig. 5a),CD4+/CD8+ cell ratio in the spleen (Fig. 5b), activation markers of CD4+ and CD8+ T cells (Fig. 5c), hematology parameters (Supplementary Table 1), serum cytokines, despite considerable mouse-to-mouse variation (Fig. 5d), or liver damage as determined by measuring alanine transaminase (ALT) or aspartate transaminase (AST) levels in the circulation (Fig. 5e). This evidence concerns the gene GPT and neoplasm.